David A. Hollander

David A. Hollander, M.D., M.B.A., joined Revance in October 2022 as Chief Medical Officer, overseeing clinical development, data science, medical affairs, scientific innovation, pharmacovigilance and regulatory affairs.

Dr. Hollander brings over 20 years of experience in the global biotech and pharma industry, spanning the entire drug development life cycle. Prior to joining Revance, he was the Chief Research & Development Officer at Aerie Pharmaceuticals, where he directed preclinical research and clinical development in the U.S., Europe and Japan, and led the company’s medical affairs, regulatory and quality organizations. Previously, he was the Chief Medical Officer at Ora, Inc., where he oversaw medical operations across pharmaceutical and device clinical development, preclinical studies, as well as research and development into new regulatory endpoints. Dr. Hollander began his industry career at Allergan, Inc., where he spent a decade serving in roles of increasing responsibility, including Vice President, Global Therapeutic Area Head in Clinical Development for Anterior Segment and Consumer Eye Care. Dr. Hollander currently serves as a Board Member for Kiora Pharmaceuticals and the Arnold & Mabel Beckman Foundation.

Dr. Hollander received his B.S. in chemistry with honors and distinction from Stanford University, earned his medical degree at the University of Pennsylvania School of Medicine, and obtained an M.B.A. in Health Care Management from the Wharton School. He completed his residency in ophthalmology at the University of California, San Francisco, and a Heed Fellowship in Cornea, External Disease, and Refractive Surgery at the Jules Stein Eye Institute, University of California, Los Angeles.